Dr Supriya Shidhaye, Principal of VES College of Pharmacy, bags Best Principal Award 2024-25

IMT News Desk
IMT News Desk
· 2 min read

Dr Shidhaye also served the University as Chairperson and later as a member of the Board of Studies in Pharmacy for over eight years

Vivekanand Education Society (VES) announced that Dr Supriya Shidhaye, Principal of VES College of Pharmacy, was conferred with the prestigious Best Principal Award 2024-25 – Urban Area by the University of Mumbai. The award took into consideration parameters such as individual research, grants, publications, patents, new academic programmes initiated, the autonomous status of the college, and contributions to the University of Mumbai. Dr Shidhaye also served the University as Chairperson and later as a member of the Board of Studies in Pharmacy for over eight years.

The award was presented by Kiren Rijiju, Minister of Minority Affairs and Parliamentary Affairs, Government of India, along with Prof (Dr) Ravindra Kulkarni, Vice Chancellor, University of Mumbai, at a grand felicitation ceremony that celebrated excellence in educational leadership. The University of Mumbai, with over 885 affiliated colleges spanning disciplines such as humanities, commerce, science, architecture, law, management, and pharmacy, recognised Dr Shidhaye’s exceptional contributions in the category of Urban Colleges – Pharmacy.

“I am humbled to receive this recognition from the University of Mumbai. This award was not just a personal milestone but a reflection of the collective spirit, hard work, and perseverance of the entire VES College of Pharmacy fraternity. Together, our faculty, staff, and students continuously strive to create an ecosystem of academic innovation, global relevance, and social impact. I dedicated this achievement to the VES Management, whose unwavering support and commitment had been the cornerstone of our success. Going forward, we would continue to strengthen our contributions to healthcare education and research, in service of society and the nation,” said Dr Shidhaye.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk